Bexion Pharmaceuticals

Formulation of a synthetically produced, human lysosomal protein for the potential treatment of glioblastoma.

placeCovington, Kentucky, United States calendar_todayFounded 2006 groups48 employees language bexionpharma.com

Registered entities

Investor mix

5 investors on record.

Investor typeCountShare
Venture capital360%
Other / undisclosed240%
Coming soon